First time users: You will need to check your degree as you created an ACMG account. The system designates educational credits according to your degree. Be sure you are logged in (do you see your name on the top right under the ACMG Genetics Academy logo?). If not, login before proceeding.
NCC Knowledge Nugget Series: SMA ACT Sheet
Date of Release: May 17, 2021
CME expiration date: May 17, 2024
Estimate time of completion: 15 minutes (.25 CME)
Course must be completed by the expiration date
www.acmgeducation.net
Session Description
The ACMG ACT Sheets and Algorithms are a clinical decision support tool for non-genetics providers that describe the short term actions a health professional should follow in communicating with the family and determining the appropriate steps in the follow-up of the infant that has screened positive. To offer a more active and engaging educational opportunity to accompany the ACT Sheets, the National Coordinating Center for the Regional Genetics Networks (NCC) is launching the Knowledge Nugget Series. These quick sessions allow providers to review the existing ACT Sheets and provide a deep dive into a particular ACT Sheet through an animated video. The first video in the series is the Knowledge Nugget: SMA ACT Sheet.
Target Audience
- Non-genetics providers: Primary care providers, pediatricians, family physicians, nurse practitioners, physician assistants
- Clinical geneticists; genetic counselors; pediatric, obstetric, and maternal-fetal specialists; and all medical practitioners who are providing comprehensive diagnostic, management, and counseling services for patients with, or at risk for, genetically influenced health problems.
Agenda
- Review the Spinal Muscular Atrophy (SMA) ACMG Newborn Screening ACT Sheet.
- Watch the Knowledge Nugget SMA ACT Sheet Video to review the ACT Sheet
- Answer the test questions related to the ACT Sheet.
Learning Objectives
At the conclusion of this session, participants should be able to:
- Identify the purpose of the ACMG ACT Sheets.
- Describe how a newborn screening differs from a confirmatory test.
- List the next steps a provider should take once they receive a positive newborn screening result for SMA.
Presenter(s):
Renee Rider, JD, MS
Fellow, NIH-ACMG Genomic Medicine Program Management
American College of Medical Genetics and Genomics
Financial Disclosures
Disclosure Statement
It is the policy of the American College of Medical Genetics and Genomics to plan and implement all of its educational activities in accordance with the ACCME Essentials and Areas and ACCME® Policies to ensure balance, independence, objectivity and scientific rigor. In accordance with the ACCME® Standards for Commercial Support, everyone (speakers, moderators, committee members and staff) who is in a position to control the content of an educational activity certified for AMA PRA Category 1 Credit™ is required to disclose all financial relationships with any commercial interests (see definition below) within the past 12 months that creates a real or apparent conflict of interest. Disclosure must include financial relationships of the individual and those of their spouse/partner. Individuals who do not disclose will be disqualified from participating in a CME activity.
This disclosure pertains to relationships with ACCME-defined commercial interests whose products or services may be related to the subject matter of the presentation topic. Any real or apparent conflicts of interest related to the content of the presentations must be managed prior to the educational activity. ACMG will identify, review and resolve all conflicts of interests prior to an educational activity being delivered to learners.
NOTE:
ACMG will follow the ACCME’s expectation that no employees or owners of commercial interests will be involved as planners/faculty/presenters of a CME accredited activity.
The ACCME definition of a commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.
The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.
Diagnostic laboratories are not considered commercial interests unless they are owned by or have a sister organization which is a commercial interest.
Planning Committee and ACMG Staff*
The following have nothing to disclose.
Joann Bodurtha, MD, MPH
Alisha Keehn, MPA
Megan Lyon, MPH
*Jane Radford, MHA, CHCP
Renee Rider, JD, MS
Nancy Rose, MD
Presenters Disclosure
Renee Rider, JD, MS
Nothing to Disclose
Educational Credit
Accreditation Statement
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement
The American College of Medical Genetics and Genomics designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Claiming your Educational Credits
Pass a post-test with a score of 80% or better. Complete the activity evaluation form.
HIPAA Compliance
The ACMG supports medical information privacy. While the ACMG is not a “covered entity” under HIPAA 1996 and therefore is not required to meet these standards, ACMG wishes to take reasonable steps to ensure that the presentation of individually identifiable health information at ACMG-sponsored events has been properly authorized. All presenters have completed a form indicating whether they intend to present any form of individually identifiable healthcare information. If so, they were asked either to attest that a HIPAA-compliant consent form is on file at their institution, or to send ACMG a copy of the ACMG HIPAA compliance form. This information is on record at the ACMG Administrative Office and will be made available on request.
Content Validation
ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
Content Validation and Fair Balance
- ACMG follows the ACCME policy on Content Validation for CME activities, which requires:
- All recommendations involving clinical medicine must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients.
- All scientific research referred to, reported or used in CME in support or justification of patient care recommendations must conform to the generally accepted standards of experimental design, data collection and analysis.
- Activities that fall outside the definition of CME/CE; “Educational activities that serve to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public, or the profession” (source: ACCME and AMA) will not be certified for credit. CME activities that promote recommendations, treatment, or manners of practicing medicine or pharmacy that are not within the definition of CME/CE or, are known to have risks or dangers that outweigh the benefits or, are known to be ineffective in the treatment of patients.
- Presentations and CME/CE activity materials must give a balanced view of therapeutic options; use of generic names will contribute to this impartiality. If the CME/CE educational materials or content includes trade names, where available, trade names from several companies must be used.
Off-label Uses of Products
When an off-label use of a product, or an investigational use not yet approved for any purpose, is discussed during an educational activity, the accredited sponsor shall require the speaker to disclose that the product is not labeled for the use under discussion, or that the product is still investigational. Discussions of such uses shall focus on those uses that have been subject of objective investigation.
Disclaimer
The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or test, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.
NCC Funding Acknowledgement
This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under Cooperative Agreement #UH9MC30770 from 6/2020-5/2024 for $800,000 per award year. This information or content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government.